Ivabradine for MINS: A Beta-Blocker Alternative? 09/01/25
Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like bleeding and NOTION-2 trial. Key takeaway: Ivabradine for MINS: A Beta-Blocker Alternative?.
Article Links:
Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation)
Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation)
Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation)
Article 4: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation)
Article 5: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation)
<p>Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/ivabradine-for-mins-a-beta-blocker-alternative-09-01-25/</p> <h3>📋 Full Episode Summary</h3> <p>This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.</p> <h3>📚 Featured Articles</h3> <h4>Article 1: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884774″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884774</a></p> <p><strong>Summary:</strong> This multicenter randomized controlled trial evaluated whether using biomarker-based Atrial Fibrillation Better Care risk scores to guide treatment decisions improves outcomes in patients with atrial fibrillation. The study informed investigators of each patient’s ABC-AF-stroke, bleeding, and heart failure risk scores to guide multidimensional treatments; however, the full results and clinical implications will be crucial to understanding its impact.</p> <h4>Article 2: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884771″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884771</a></p> <p><strong>Summary:</strong> This randomized controlled trial investigated ivabradine, a selective heart rate-lowering agent, to prevent myocardial injury after noncardiac surgery. The study compared ivabradine to placebo in patients at risk for atherosclerotic disease undergoing noncardiac surgery, aiming to reduce perioperative myocardial infarction without the hemodynamic instability associated with beta-blockers.</p> <h4>Article 3: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis.</h4> <p><strong>Journal:</strong> Circulation</p> <p><strong>PubMed Link:</strong> <a href=”https://pubmed.ncbi.nlm.nih.gov/40884768″ target=”_blank”>https://pubmed.ncbi.nlm.nih.gov/40884768</a></p> <p><strong>Summary:</strong> The NOTION-2 trial’s three-year follow-up compared tran… (Full details on website)